Your session is about to expire
← Back to Search
Memantine for Parkinson's Disease
Study Summary
This trial is studying how well memantine works in slowing down the progression of Lewy Body Dementia (LBD) by using MRI brain imaging and comparing it to a placebo.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 4 trial • 115 Patients • NCT01902004Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Do elderly patients fit the age criteria for this clinical trial?
"The guidelines for who can participate in this clinical trial state that the minimum age is 45 and the maximum age is 85."
Could I potentially take part in this research?
"This study, which is seeking 50 participants that suffer from parkinson's disease, has specific inclusion criteria. Most notably, potential patients must be between 45 and 85 years old, have been diagnosed for at least 2 years, and be able to give informed consent."
What is the FDA's current stance on Memantine?
"Memantine's Phase 3 status indicates that, while there is data supporting its efficacy, there are also multiple rounds of data attesting to the medication's safety. Therefore, it received a score of 3."
How many individuals have signed up for this experiment?
"That is right, the clinical trial is still looking for participants. According to the information on clinicaltrials.gov, the study was posted on April 1st, 2019 and updated on June 29th, 2020. The research team wants to enroll 50 individuals at a single site."
Why was this research project undertaken?
"The primary outcome of this study is to evaluate the Change from baseline Trail test at year 1 time frame. The secondary outcomes include the Change in Intracellular volume (ICV), as measured by MRI NODDI sequence, in multiple brain regions, defined as ICV component is calculated from the NODDI MRI, using available software, for dorsolateral prefrontal cortex, precuneous, anterior cingulate, posterior cingulate, hippocampus, entorhinal cortex, thalamus, caudate, putamen, association visual cortex and primary visual cortex. The change in ICV fro each region will be"
Can new patients still join this clinical trial?
"Yes, as of today this clinical trial is still recruiting patients. The original posting was on April 1st, 2019 with the latest update being June 29th, 2020."
What is the research history of Memantine?
"There are currently 26 different ongoing clinical trials studying the effects of memantine. Most of these studies are Phase 3 trials, which means that there is some evidence supporting efficacy. 11 out of the 26 total trials are in their final stage. The majority of these studies originate from Geneva, Illinois; however, there are 290 locations spread across the globe conducting research on memantine."
Share this study with friends
Copy Link
Messenger